# SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fed Admin

> **NCT01330303** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 37 (actual)

## Conditions studied

- Prostatic Hyperplasia

## Interventions

- **DRUG:** Reference formulation
- **DRUG:** Test formulation

## Key facts

- **NCT ID:** NCT01330303
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-08
- **Primary completion:** 2009-12-22
- **Final completion:** 2009-12-22
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2017-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01330303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01330303, "SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fed Admin". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01330303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*